Top 17 stocks in focus today: RIL, Aurobindo, Divi’s Lab, RBL Bank
RIL may be looking at buying part of textile maker Alok Industries, as per media reports.
Divi’s Lab says USFDA withdraws warning letter for co’s Vizag unit-II.
Slab rate for tiles and sanitaryware is currently 28% and the industry has petitioned the government to lower it to 18%; final outcome will be known after the GST Council meet.
JSW Steel achieved crude steel production of 13.43 lakh tonnes in month of October 2017 compared to 13.35 lakh tonnes in October 2016, recording a growth of a mere 1%.
Mercator announces closure of QIP. To issue 3.25 crore shares at an issue price of Rs 44.65.
Jagran Prakashan sold stake in Naidunia Media Ltd for Rs 5 lakh.
NTPC commissioned 50MW wind project in Gujarat.
Reliance Home Finance to consider raising funds via QIP.
RBL Bank increased stake in Swadhaar FinServe from 28.4% to 58.4%.
Linde India lowers minimum acceptance ratio for voluntary public takeover offer from 75% to 60%.
JK Paper to consider allotment of equity shares to FCCB holders seeking conversion.
Muthoot Capital closed bidding for QIP today. Fixed Issue price at Rs 605 per share.
Seamec entered into a contract worth Rs 5.72 crore with Dolphin Offshore for deployment of vessel – Seamec Princess.
Google is in talks with Mumbai based service engine Just Dial to acquire its business, as per media reports.
NTPC alters plans of taking over stressed power plants, offers fee based management services.
The government said it has asked state owned SAIL and the world’s largest steelmaker ArcelorMittal to expedite setting up of their proposed joint venture for a Rs 5,000 crore auto-grade steel plant, as per media reports.
NCLT asked Swedish telecom equipment and services provider Ericsson to file bank certificate detailing the amount telecom service provider RCom owes it within seven days, as per media reports.
Two domestic drug makers including Zydus Cadila are under the scanner of the pharmaceutical regulator Central Drug Standards Control Organization for allegedly launching a combination drug to treat hypertension without mandatory prior approval, as per media reports.